《大行》美银上调信达生物(01810.HK)今明两年销售预测 目标价上调至61.1元

阿斯达克财经
Apr 25, 2025

美银证券发表报告表示,信达生物(01801.HK) 今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币,按年升47.6%及32.3%,达伯华销售按年升15.4%至5,150万元人民币。同时,睿妥及Tafolecimab销售分别按年升53.2%及2.13倍。该行基于主要产品强劲销售,上调今明两年销售预测1%。该行又指,公司宣布将在2025年ASCO年会进行七场报告,其中三场关于达伯舒...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10